Intravenous and Oral Itraconazole Versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial

Annals of Internal Medicine

Volumn 138, Issue 9, 2003, Pages

  Winston, Drew J ^a   Maziarz, Richard T ^b   Chandrasekar, Pranatharthi H ^b   Lazarus, Hillard M ^b   Goldman, Mitchell ^b   Blumer, Jeffrey L ^b   Leitz, Gerhard J ^b   Territo, Mary C ^b  

^a UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; ANTIFUNGAL AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; HYPOXEMIA; INFECTION RISK; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; RECIPIENT; SIDE EFFECT; TREMOR; VOMITING; BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; SURVIVAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; FEMALE; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; SURVIVAL ANALYSIS;

EID: 0037736664     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-9-200305060-00006     Document Type: Article

References (45)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant. 1999;5:55-68. [PMID: 10371357]
2. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139-44. [PMID: 11418871]
3. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-51. [PMID: 1542320]
4. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-52. [PMID: 7769290]
5. Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med. 1994;97:509-14. [PMID: 7985709]
6. O'Donnell MR, Schmidt GM, Tegtmeier BR, Faucett C, Fahey JL, Ito J, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol. 1994;12:827-34. [PMID: 8151325]
7. Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant. 2000;25:853-9. [PMID: 10808206]
8. Tollemar J, Ringdén O, Andersson S, Sundberg B, Ljungman P, Tydén G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12:577-82. [PMID: 8136741]
9. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999;23:163-8. [PMID: 10197802]
10. Meunier F. Prevention and mycoses in immunocompromised patients. Rev Infect Dis. 1987;9:408-16. [PMID: 3296106]
11. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999;93:3654-61. [PMID: 10339471]
12. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-7. [PMID: 1669837]
13. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993;37:1847-9. [PMID: 8239594]
14. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309-16. [PMID: 10608780]
15. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319-24. [PMID: 11303267]
16. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-17. [PMID: 11880955]
17. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12:40-79. [PMID: 9880474]
18. De Beule KL. Itraconazole: pharmacology, clinical experience, and future development. Int J Antimicrob Agents Chemother. 1996;6:175-81.
19. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell'Adulto. Clin Infect Dis. 1999;28:250-5. [PMID: 10064240]
20. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol. 1999; 105:901-11. [PMID: 10554799]
21. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother. 2000;44:1887-93. [PMID: 10858349]
22. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412-22. [PMID: 11560454]
23. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292: 895-902. [PMID: 235092]
24. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-76. [PMID: 7004534]
25. 3H RIA. Am J Clin Pathol. 1987;87:528-32. [PMID: 3826016]
26. Warnock DW, Turner A, Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother. 1988;21:93-100. [PMID: 2833490]
27. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Tentative standard. NCCLS document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
28. Espinel-Ingroff A, Bartlett M, Bowden R, Chin NX, Cooper C Jr, Fothergill A, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol. 1997;35:139-43. [PMID: 8968895]
29. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14. [PMID: 11731939]
30. SAS Institute, Inc. User's Manual. SAS Version 6.12 Software. Cary, NC: SAS Institute, Inc.; 1996.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statistical Association. 1958;53:457-81.
32. Rosenbaum PR, Dubin DB. Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association. 1984;79:516-24.
33. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982;3:345-53. [PMID: 7160191]
34. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991;164:731-40. [PMID: 1894935]
35. Wingard JR, Beals SU, Santos GW, Merz WG, Saral R. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant. 1987;2:175-81. [PMID: 3332165]
36. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-66. [PMID: 9180187]
37. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kähkölä, Ruutu T. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997;19:801-8. [PMID: 9134172]
38. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood. 1994;84:1328-32. [PMID: 8049448].
39. van Burik JH, Leisenring W, Myerson D, Hackman RC, Shulman HM, Sale GE, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore). 1998;77:246-54. [PMID: 9715729]
40. Schmidt U, Pfaffenbach B, Quabeck K, Donhuijsen K. [Fungal infections after bone marrow transplantation - an autopsy study]. Mycoses. 1991;34 Suppl 1:33-5. [PMID: 1818260]
41. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055-61. [PMID: 10979947]
42. Glasmacher A, Hahn C, Molitor E, Sauerbruch T, Marklen G, Schmidt-Wolf IGH. Definition of an itraconazole target concentration for antifungal prophylaxis [Abstract]. Abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2000; Toronto, Canada. Washington: American Society for Microbiology; 2000:363.
43. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol. 1991;32:624-6. [PMID: 1659439]
44. Leather HL, Boyette R, Wingard JR. Evaluation of the pharmacokinetic drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin in allogeneic bone marrow transplant patients [Abstract]. Blood. 2000;96:3909.
45. Crippa F, Corey L, Leisenring W, Hoyle M, Boeckh M, Marr K. Administration of itraconazole for antifungal prophylaxis in stem cell transplant recipients: levels and drug interactions [Abstract]. Abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2000; Toronto, Canada. Washington: American Society for Microbiology; 2000:25.